Announced Fri, 10 Apr · 17:11 IST

Summary of Proceeding of EGM

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹39.87
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.0+6.1+8.2+10.3+8.2+12.5+2.3-6.9-4.1-14.0
Up moveDown movePending
AI summary

Rekvina Laboratories held its first EGM of FY2026-27 on April 10, 2026, at its registered office in Vadodara, from 11:30 AM to 11:50 AM. A total of 17 members attended in person, and the meeting was chaired by Managing Director Mr. Amit Mukesh Shah. Six special business items were placed before members for approval, including an increase in authorised share capital with corresponding amendment to the MOA, alteration of Articles of Association, raising Section 186 limits for investments/loans/guarantees, approval of related party transactions, and two separate preferential equity issues — one for non-cash consideration and one for cash to non-promoters. Members raised queries about the company's fund-raising plans, which the MD addressed. Voting was conducted through polling papers under the supervision of Scrutinizer Mr. Suhas Bhattbhatt; results are pending in a separate report.

Likely market impact

If approved, these resolutions would allow the company to raise fresh capital via preferential issues and modify its capital and governance framework. The actual voting outcomes, still awaited from the Scrutinizer, are the key trigger — successful passage would enable potential equity dilution for existing shareholders and define the size of the fund-raise.